

Aminocaproic acid injection, Epinephrine injection, Molindone tablets – Drug shortages

- The drug shortages of <u>aminocaproic acid</u> injection, <u>epinephrine</u> 0.1 mg/mL injection, and <u>molindone</u> tablets are ongoing. <u>Aminocaproic acid</u> injection, <u>epinephrine</u> injection, and <u>molindone</u> tablets have been unavailable for at least 90 days.
 - Hospira's estimated availability of aminocaproic acid injection is late November 2017.
 Hospira estimates that the product will be fully recovered by March 2018.
 - Amphastar and Hospira's estimated availability of epinephrine injection is November 2017.
 Epinephrine auto-injectors (eg, EpiPen[®]) are readily available.
 - Epic's estimated availability of molindone tablets is unknown.

Product Description	NDC #
Aminocaproic acid 5 g/20 mL (250 mg/mL) injection	0409-4346-73, 0409-4346-09, 0409-4346-10
Epinephrine 0.1 mg/mL injection	76329-3316-1, 0409-4921-34
Molindone 5 mg, 10 mg and 25 mg tablets	64720-228-10, 64720-229-10, 64720-230-10

- Aminocaproic acid injection is useful in enhancing hemostasis when fibrinolysis contributes to bleeding. In life-threatening situations, fresh whole blood transfusions, fibrinogen infusions, and other emergency measures may be required.
- Epinephrine injection is indicated for intravenous injection in (1) treatment of acute hypersensitivity
 (anaphylactoid reactions to drugs, animal serums and other allergens), (2) treatment of acute
 asthmatic attacks to relieve bronchospasm not controlled by inhalation or subcutaneous
 administration of other solutions of the drug and (3) treatment and prophylaxis of cardiac arrest and
 attacks of transitory atrioventricular heart block with syncopal seizures (Stokes-Adams Syndrome).
- Molindone is indicated for the management of schizophrenia.



optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.